AAAR 33rd Annual Conference
October 20 - October 24, 2014
Rosen Shingle Creek
Orlando, Florida, USA
Abstract View
Reformulation of Abandoned Wortmannin into Biodegradable Nanoparticles for Lung Cancer Treatment
HSI-WEI YEH, Da-Ren Chen, Virginia Commonwealth University
Abstract Number: 200 Working Group: Health Related Aerosols
Abstract Lung cancer is the most ordinarily diagnosed cancer worldwide. Despite the continuous advancement of therapies for various cancers, the development of effective ones against lung cancer remains stagnant. The efficacy of currently available medicines is unsatisfactory because of the late appearance of symptoms. Alarmingly, these medications could even be toxic when applied to patients at high doses via either improper administration routes or pharmaceutical dosage forms. Safer and more effective new therapies are in high demand for lung cancer patients. To meet such unmet medical needs, much efforts have been made for the development of brand new chemical entities. However, the decreasing success rate of these compounds during clinical development, and the time and capital consumption in the development process impede the industry to efficiently translate the research results into drug products. Reformulating abandoned drugs which have been proven with excess toxicity yet with great therapeutic effects could be one strategy to the answer of the aforementioned challenge. Because of the unique properties of nanoparticles (NPs) to target tumors, they are promising drug carriers to reformulate abandoned drugs and to release them in controlled manner for the lowest toxicity. The feasibility of the concept has been proven by encapsulation of Wortmannin in biodegradable NPs generated in liquid phase for radiation therapy. However, the concept hasn’t been studied for lung cancer treatment. Electrospray (ES) technology is a promising tool for generating drug carriers (in the particle form) with superior controlled release performance compared with those generated by liquid-phase systems. In this study, we encapsulated Wortmannin with Poly(Lactide-co-Glycolide) (PLGA) NPs generated by a dual-capillary ES System to reduce the side effect while keeping sufficient drug dose concentration at the site of action. The release profiles of as-produced nanoparticles in various sizes were characterized. The detail of this study will be given in this presentation.
Keywords: Lung cancer treatment, Nanoparticles, Wortmannin, Biodegradable polymer